

		Chronic	
		CML	CLL
1 <sup>st</sup> Line Treatment		<p>SPiRiT 3 (D, P)</p> <p>CANC 3282 (Y)</p> <p>NCRN 3023 (Y)</p>	<p>RiAlto (D, P)</p> <p>CLL210 (Y)</p> <p>NCRN 460 (C, I)</p> <p>COSMIC Version 2.0 (D, P)</p> <p>NCRN 3025 (C, I)</p> <p>NCRN580/ RESONATE 1116 (C, I)</p> <p>NCRN2442 (C, I)</p> <p>CANC 3253 (Y)</p> <p>Phase I trial of DI-B4 (O, A)</p> <p>NCRN 546 (O, I)</p> <p>NCRN - 2800 (C, I)</p> <p>CLARET (D, P)</p> <p>FLAIR (D, P)</p> <p>GALACTIC (Y)</p> <p>CANC 3652 (C, I)</p>
2 <sup>nd</sup> Line Treatment/ MRD Positive		<p>WT1 TCR-001 (C, A)</p> <p>Matchpoint (D, P)</p> <p>CANC 3703 (O, I)</p>	<p>CLL210 (Y)</p> <p>NCRN 460 (C, I)</p> <p>COSMIC Version 2.0 (D, P)</p> <p>NCRN 3025 (C, I)</p> <p>NCRN580/ RESONATE 1116 (C, I)</p> <p>NCRN2442 (C, I)</p> <p>CANC 3253 (Y)</p> <p>Phase I trial of DI-B4 (O, A)</p> <p>NCRN 546 (O, I)</p> <p>NCRN - 2800 (C, I)</p>
Supportive Care	<p>NCRN436 (O, I)</p> <p>CANC 3253: Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in pts with refractory/ relapsed Richter's Transformation</p> <p>CANC 3282: Treatment free remission (TFR) rate in Ph+ CML after nilotinib</p> <p>CANC 3652: Idelalisib in combination with Rituximab in previously untreated CLL pts with 17p deletion</p> <p>NCRN 436: Safety, immunogenicity &amp; efficacy of GSK Biologicals Herpes Zoster HZ/su candidate vaccine</p> <p>NCRN 460: Dose finding and safety study of GDC-0199 &amp; Obinutuzumab</p> <p>NCRN 546: PCI-32765 (Ibrutinib) Long-term Extension Study</p> <p>NCRN580: Open-label extension study in pts with CLL or SLL who participated in 'PCI-32765 vs Chlorambucil'</p> <p>NCRN2442: ABT 199 (GDC-0199) in Relapsed/Refractory CLL</p> <p>NCRN2800: IPI-145 vs Ofatumumab in relapsed/refractory CLL</p> <p>NCRN3023: Bosutinib vs Imatinib in newly diagnosed chronic phase Ph+ CML</p> <p>NCRN3025: GDC-0199 (ABT199) + Rituximab vs Bendamustine + Rituximab</p> <p>* - for patients under 18 years Combination with Bendamustine + Rituximab</p> <p>** - for patients stopping first line treatment</p> <p>*** - study suspended</p>	<p>NCRN436 (O, I)</p>	
Cohort Studies	<p>Leuk' Associated Antigens (O, A)</p>	<p>Mathematical modelling (O, A)</p> <p>DNA Damage Repair Defects (O, A)</p> <p>Genetic Epidemiology of CLL*** (C, A)</p> <p>IciCLLe (D, P)</p>	